Corporate Profile
Corporate History
| August 2007 |
Established Momotaro-Gene Inc. in Okayama City, Okayama Prefecture, for research and development of REIC, a cancer suppressor gene, licensing research results, and bridging for commercialization |
|---|---|
| November 2007 |
Acquired exclusive licenses of REIC basic patent and prostate cancer cell apoptosis inducer patent |
| December 2007 |
Acquired exclusive licenses of cancer therapeutic drug patents containing the partial fragment of REIC gene |
| August 2008 |
Angel tax system preliminary approval (Chugoku Bureau of Economy, Trade and Industry No. 1） |
| October 2008 |
Headquarters moved to Okayama Medical Innovation Center (OMIC) Incubation Facility |
| June 2009 |
Production of GMP adeno REIC started (NBC, UK) |
| August 2009 |
National Institute of Advanced Industrial Science and Technology (NEDO) Innovation Promotion Project (Clinical development of REIC expressing adenovirus formulation for malignant mesothelioma) adopted |
| November 2009 |
Concluded licensing agreement with EPS Co., Ltd. for manufacture, development and sales of REIC pharmaceuticals in China (with the change of organization of EPS Inc., now we conclude the same agreement with EPS(CHINA) Co., Ltd. which is a subsidiary of EPS.) |
| March 2010 |
Acceptance of IND (clinical trial) application to US Food and Drug Administration (FDA) (Phase I clinical trial for prostate cancer by adeno REIC formulation) |
| January 2011 |
Clinical research on REIC gene therapy for prostate cancer started at Okayama University Hospital |
| October 2011 |
Adopted for research achievement development project (A-STEP) by the National Institute of Science and Technology (JST) |
| May 2014 |
Phase I clinical trial started in the United States for early prostate cancer |
| July 2014 |
Signed license agreement with Kyorin Pharmaceutical for malignant mesothelioma in Japan |
| July 2014 |
Procured funds (150 million yen) from Japan Venture Capital Co., Ltd. and other three companies |
| September 2015 |
Started clinical trials for malignant mesothelioma by Kyorin Pharmaceutical |
| August 2016 |
Headquarters moved to Okayama Yanagi-machi Building (Okayama City Kita-ku) |
| March 2017 |
Procured large funds (1.12 billion yen including stock acquisition rights) from DCI Partners Co., Ltd. and other five companies |
| March 2017 |
Purchased REIC Basic patent and others 2 Patents from patent owners |
| February 2018 |
Doctor-led clinical phase I / Ib phase trial of REIC preparation for liver cancer started at Okayama University |
| September 2018 |
Acceptance of IND (clinical trial) application to US Food and Drug Administration (FDA) (Clinical trial of Ad-SEG-REIC with immunity checkpoint inhibitor incombination against malignant mesothelioma) |
| March 2019 |
Procured funds (510 million yen) from Nissay Capital Co., Ltd. and other four companies |
| September 2019 |
Phase II clinical trial with PD-1 inhibitor for malignant mesothelioma started at Baylor College of Medicine, USA |
| December 2020 |
Procured fund (90 million yen) from EPS Ekishin Co., Ltd. |
| April 2023 |
Procured fund (490 million yen) from Adreic Therapeutics Inc. |